Meeting
2020 Gastrointestinal Cancers Symposium
A phase II study of niraparib in combination with EGFR inhibitor panitumumab in patients with advanced colorectal cancer.
Authors
Olatunji B. Alese
Winship Cancer Institute, Atlanta, GA
Olatunji B. Alese , Walid Labib Shaib , Mehmet Akce , Christina Wu , Gregory B. Lesinski , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03983993
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr TPS269)
Abstract #
TPS269
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
First Author: Olatunji B. Alese
Poster
2011 ASCO Annual Meeting
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
First Author: I. Chau
Poster
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
First Author: Anup Kasi
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
First Author: Vivek Narayan